by Dr. C.H. Weaver 1/2019
A novel antibody-drug conjugate that targets ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) conjugated to monomethyl auristatin F has antitumor activity in renal cell cancer according to a study published in Clinical Cancer Research. (1)
The experimental drug known as AGS-16C3F was initially given to patients with very advanced renal cell carcinoma to determine the optimal dose. The study authors reported 3 partial responses and a tolerable side effect profile allowing them to conclude the drug should undergo continued evaluation in a phase II trial.
The main side effect reported was a reversible keratopathy. Overall approximately half of the patients reported eye-related adverse symptoms which were reversible. For patients with advanced renal cell carcinoma participation in clinical trials evaluating drugs that target ENPP3 should be considered.
- Thompson JA, Motzer RJ, Molina AM, et al. Phase 1 trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res. 2018;24(18):4399-4406.